US launches Section 301 trade probe into Germany drug pricing

The Trump administration has initiated a Section 301 trade investigation against Germany, accusing it of underpricing innovative pharmaceutical products at the expense of American patients. USTR Jameson Greer confirmed the probe will examine whether Germany's pricing policies constitute an unfair trade burden. The move follows months of negotiations, with Washington urging Berlin to adopt a deal similar to the recent US-UK pharmaceutical pricing agreement.